SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 188 filers reported holding SANGAMO THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is 0.71 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $199,000 | -85.3% | 26,500 | -82.3% | 0.00% | -100.0% |
| Q3 2021 | $1,352,000 | -60.5% | 150,000 | -47.6% | 0.00% | -66.7% |
| Q2 2021 | $3,424,000 | +257.8% | 286,000 | +274.7% | 0.00% | +200.0% |
| Q1 2021 | $957,000 | -20.8% | 76,321 | -1.4% | 0.00% | 0.0% |
| Q4 2020 | $1,208,000 | +84.4% | 77,420 | +11.8% | 0.00% | – |
| Q3 2020 | $655,000 | +42.1% | 69,232 | +61.4% | 0.00% | – |
| Q2 2019 | $461,000 | -66.3% | 42,900 | -64.0% | 0.00% | -100.0% |
| Q4 2018 | $1,369,000 | -32.5% | 119,217 | -0.3% | 0.00% | 0.0% |
| Q3 2018 | $2,027,000 | -45.6% | 119,600 | -54.4% | 0.00% | -60.0% |
| Q2 2018 | $3,727,000 | +375.4% | 262,468 | +449.0% | 0.01% | +400.0% |
| Q4 2017 | $784,000 | +49.3% | 47,810 | +36.6% | 0.00% | 0.0% |
| Q3 2017 | $525,000 | +70.5% | 35,000 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $308,000 | -54.4% | 35,000 | -76.0% | 0.00% | 0.0% |
| Q3 2016 | $675,000 | +457.9% | 145,800 | +1234.9% | 0.00% | – |
| Q2 2015 | $121,000 | – | 10,922 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Golden State Equity Partners | 154,360 | $897,000 | 0.45% |
| Rhenman & Partners Asset Management AB | 761,429 | $4,424,000 | 0.44% |
| Lombard Odier Asset Management (Switzerland) SA | 860,702 | $5,001,000 | 0.39% |
| WASATCH ADVISORS LP | 10,576,997 | $61,452,000 | 0.30% |
| Rokos Capital Management LLP | 977,663 | $5,861,000 | 0.27% |
| KLK CAPITAL MANAGEMENT LLC | 44,323 | $258,000 | 0.26% |
| Long Focus Capital Management, LLC | 340,000 | $1,975,000 | 0.25% |
| Vanguard Capital Wealth Advisors | 33,380 | $193,000 | 0.14% |
| Fort Sheridan Advisors LLC | 73,978 | $430,000 | 0.13% |
| Delphia (USA) Inc. | 20,983 | $122,000 | 0.09% |